2012 Scrip 100: Love for the unloved – reinventing Foscavir
This article was originally published in Scrip
Executive Summary
The tail end of the lifecycle does not have to be the closing chapter for pharmaceutical products. From its launch in the late 1980s until 2010, AstraZeneca marketed the antiviral Foscavir (foscarnet sodium) as a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"